# Mayne Pharma Reports 52% Fall in Quarterly Underlying Earnings

The company’s unaudited update shows weaker dermatology sales offsetting growth elsewhere, with quarterly revenue down 2%.

By Will Langan | 24X7 News
Published: 2026-10-26T00:02:18.986Z
Updated: 2026-10-26T00:02:18.986Z
Section: Money
Format: News
Canonical: https://24x7news.us/articles/mayne-pharma-quarterly-earnings-october-26-2026

Mayne Pharma reported first-quarter underlying earnings before interest, tax, depreciation and amortisation of A$5.3 million, down 52% from A$11 million a year earlier, according to its October 26 ASX announcement.

Revenue for the three months ended September 30 fell 2% to A$95.7 million, while gross profit declined 8% to A$60.3 million.

The company attributed the weaker performance to lower dermatology sales after generic competition and other commercial pressures, alongside planned investment in its women’s health business.

The underlying measure excludes several costs. Reported EBITDA was a loss of A$1.6 million after A$6.9 million in non-recurring items. The figures are unaudited company results, released Monday morning in Australia.

## Sources
- Mayne Pharma ASX announcement — October 26, 2026: https://announcements.asx.com.au/asxpdf/20261026/pdf/075rnwfkwnmchj.pdf
- Capital Brief — October 26, 2026: https://www.capitalbrief.com/briefing/mayne-pharma-posts-52-drop-in-q1-earnings-on-competitive-pressures-5ca7335c-743d-4873-b157-048a96233117/